Trial Profile
Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, but Still Complaining of Excessive Daytime Sleepiness
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pitolisant (Primary)
- Indications Hypersomnia; Sleep apnoea syndrome
- Focus Therapeutic Use
- Acronyms HAROSA III
- Sponsors Bioprojet
- 07 Jul 2020 Status changed from active, no longer recruiting to completed.
- 20 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2018 Planned End Date changed from 24 Mar 2017 to 1 Mar 2020.